Switch Therapeutics

Switch Therapeutics, founded with a mission to revolutionize RNA interference (RNAi) therapies, focuses on integrating nucleic acid nanotechnology to treat a variety of diseases, particularly those affecting the central nervous system. The company's core product is its proprietary Conditionally Activated siRNA (CASi) platform, which combines the advantageous properties of single and double-stranded RNA into a single molecule, enabling efficient self-delivery and targeted treatment.

Notable affiliates include leading scientists and industry experts in RNAi and nanotechnology. The company has garnered attention from prominent investors in the biotech sector, reflecting confidence in its innovative approach. Key achievements include significant advancements in their CASi platform, positioning Switch Therapeutics as a transformative player in genetic medicine. Their impact lies in potentially offering groundbreaking treatments for previously challenging medical conditions.